TSFAE24b:	Overall Summary of [Treatment-emergent Adverse Events] by Toxicity Grade; Safety Analysis Set (Study jjcs - core)				
 	Active Study Agent 	Active Study Agent 	 	
 	Xanomeline High Dose 	Xanomeline Low Dose 	Placebo 	
n (%) 	N=53 	N=73 	N=59 	
Subjects with ≥ 1 AE 	51 (96.2%) 	62 (84.9%) 	42 (71.2%) 	
 	 	 	 	
Toxicity grade 	 	 	 	
Grade 5 	34 (64.2%) 	32 (43.8%) 	25 (42.4%) 	
Grade 4 	10 (18.9%) 	16 (21.9%) 	4 (6.8%) 	
Grade 3 	4 (7.5%) 	4 (5.5%) 	6 (10.2%) 	
Grade 2 	3 (5.7%) 	6 (8.2%) 	3 (5.1%) 	
Grade 1 	0 	1 (1.4%) 	3 (5.1%) 	

Note: The worst toxicity event experienced by the subject is used. If a subject has all adverse events with missing toxicities, the subject is only counted as missing. 	
Note: The worst toxicity event experienced by the subject is used. If a subject has all adverse events with missing toxicities, the subject is only counted as missing.	
Note: The worst toxicity event experienced by the subject is used. If a subject has all adverse events with missing toxicities, the subject is only counted as missing.	
Note: The worst toxicity event experienced by the subject is used. If a subject has all adverse events with missing toxicities, the subject is only counted as missing.	
Note: Toxicity grade is evaluated according to NCI-CTCAE version 5.0.. 	: Toxicity grade is evaluated according to NCI-CTCAE version 5..	: Toxicity grade is evaluated according to NCI-CTCAE version 5..	: Toxicity grade is evaluated according to NCI-CTCAE version 5..